Citius Pharmaceuticals, Inc. (CTXR) 10-Year Financial Performance & Capital Metrics

CTXR • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.Show more

Revenue $0
EBITDA -$42M -14.4%
Net Income -$39M -20.3%
EPS (Diluted) -5.97 -7.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -47.29% -41.6%
ROIC -46.13% -7.0%
Debt/Equity 0.00 -32.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Shares diluted 14.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM-14.64%

ROCE

10Y Avg-50.01%

5Y Avg-38.21%

3Y Avg-36.44%

Latest-47.01%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	1.34K	2.63K	1.75K	893	152.36K	164.87K	179.68K	194.32K	209.61K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-1.34K	-2.63K	-1.75K	-893	-152.36K	-164.87K	-179.68K	-194.32K	-209.61K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-0.96%	0.33%	0.49%	-169.62%	-0.08%	-0.09%	-0.08%	-0.08%
Operating Expenses+	3.23M	7.45M	9.99M	13.79M	15.6M	17.71M	23.53M	33.32M	36.73M	42M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.43M	4.52M	7.05M	7.23M	7M	8.9M	11.29M	15.66M	21.91M	18.25M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	1.8M	2.93M	2.94M	6.56M	8.6M	8.81M	12.24M	17.66M	14.82M	11.91M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	11.84M
Operating Income+	-3.23M	-7.45M	-9.99M	-13.79M	-15.6M	-17.71M	-23.53M	-33.32M	-36.73M	-42M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.8%	-1.31%	-0.34%	-0.38%	-0.13%	-0.14%	-0.33%	-0.42%	-0.1%	-0.14%
EBITDA+	-3.23M	-7.45M	-9.98M	-13.79M	-15.6M	-17.56M	-23.37M	-33.14M	-36.54M	-41.79M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.31%	-0.34%	-0.38%	-0.13%	-0.13%	-0.33%	-0.42%	-0.1%	-0.14%
D&A (Non-Cash Add-back)	3.07K	1.34K	2.63K	1.75K	893	152.36K	164.87K	179.68K	194.32K	209.61K
EBIT	-2.89M	-7.45M	-9.99M	-12.52M	-15.55M	-17.53M	-23.04M	-33.06M	-31.97M	-38.85M
Net Interest Income+	-4.43K	-8.19K	-849.98K	0	36.22K	52.39K	250.99K	0	1.18M	758K
Interest Income	3.07K	806	806	0	52.66K	68.07K	261.82K	251.4K	1.18M	758K
Interest Expense	7.5K	8.99K	850.79K	15.84K	16.44K	15.67K	10.84K	251.4K	0	0
Other Income/Expense	327.66K	-846.41K	-398.64K	1.25M	36.22K	162.6K	477.46K	251.4K	4.77M	3.15M
Pretax Income+	-2.9M	-8.3M	-10.38M	-12.54M	-15.56M	-17.55M	-23.05M	-33.06M	-31.97M	-38.85M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	4.43K	8.99K	0	0	16.44K	0	0	576K	576K	576K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.02%	1.02%	1.01%
Net Income+	-2.9M	-8.3M	-10.38M	-12.54M	-15.58M	-17.55M	-23.13M	-33.64M	-32.54M	-39.14M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.28%	-1.86%	-0.25%	-0.21%	-0.24%	-0.13%	-0.32%	-0.45%	0.03%	-0.2%
Net Income (Continuing)	-2.9M	-8.3M	-10.38M	-12.54M	-15.56M	-17.55M	-23.05M	-33.64M	-32.54M	-39.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	600.38K	600.38K	600.38K	4.02M
EPS (Diluted)+	-1.37	-2.29	-1.89	-1.17	-0.77	-0.45	-5.64	-5.76	-5.57	-5.97
EPS Growth %	-0.44%	-0.67%	0.17%	0.38%	0.34%	0.42%	-11.53%	-0.02%	0.03%	-0.07%
EPS (Basic)	-1.37	-2.29	-1.89	-1.17	-0.77	-0.45	-5.64	-5.76	-5.57	-5.97
Diluted Shares Outstanding	141.49K	241.55K	365.5K	715.46K	1.34M	2.61M	7.24M	9.74M	10.09M	11.59M
Basic Shares Outstanding	141.49K	241.55K	365.5K	715.46K	1.34M	2.61M	7.24M	9.74M	9.74M	11.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	736.14K	892.84K	3.42M	10.06M	7.94M	13.98M	72.81M	44.56M	34.37M	14.22M
Cash & Short-Term Investments	676.14K	294.35K	3.2M	9.18M	7.89M	13.86M	70.07M	41.71M	26.48M	3.25M
Cash Only	676.14K	294.35K	3.2M	9.18M	7.89M	13.86M	70.07M	41.71M	26.48M	3.25M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	818.34K	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	8.27M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	14.4K
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	5.4K	21.06M	20.99M	20.99M	21.04M	29.79M	69.61M	69.44M	69.24M	102.43M
Property, Plant & Equipment	0	3.74K	3.24K	1.48K	590	987.78K	829.85K	650.17K	455.86K	246.25K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	1.59M	1.59M	1.59M	1.59M	9.35M	9.35M	9.35M	9.35M	9.35M
Intangible Assets	5.4K	19.4M	19.4M	19.4M	19.4M	19.4M	59.4M	59.4M	59.4M	92.8M
Long-Term Investments	0	0	0	0	0	16.92M	29.18M	0	44.91M	0
Other Non-Current Assets	0	66.97K	2.17K	2.17K	57.09K	57.09K	38.06K	39.97M	-44.88M	38.06K
Total Assets+	741.54K	21.95M	24.42M	31.05M	28.99M	43.77M	142.43M	114M	103.61M	116.65M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.52%	28.6%	0.11%	0.27%	-0.07%	0.51%	2.25%	-0.2%	-0.09%	0.13%
Total Current Liabilities+	1.38M	5.18M	2.47M	3.18M	4.61M	4.1M	3.98M	4.53M	5.78M	35.81M
Accounts Payable	559.15K	909.16K	602.43K	1.57M	2.71M	1.86M	1.28M	1.17M	2.93M	4.93M
Days Payables Outstanding	-	247.09K	83.54K	327.61K	1000K	4.45K	2.83K	2.37K	5.5K	8.58K
Short-Term Debt	0	672.97K	172.97K	172.97K	172.97K	172.97K	177.24K	196.99K	218.38K	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	809.34K	2.67M	0	0	320.52K	1.65M	1.73M	1.57M	-218.38K	0
Current Ratio	0.53x	0.17x	1.39x	3.16x	1.72x	3.41x	18.28x	9.84x	5.95x	0.40x
Quick Ratio	0.53x	0.17x	1.39x	3.16x	1.72x	3.41x	18.28x	9.84x	5.95x	0.17x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	1.75M	4.99M	6.01M	5.66M	6.04M	6.4M	6.74M
Long-Term Debt	0	0	0	0	0	164.58K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	855.47K	678.23K	481.25K	262.87K	21.32K
Deferred Tax Liabilities	0	0	0	0	4.99M	4.99M	4.99M	5.56M	6.14M	6.71M
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	1.38M	5.18M	2.47M	3.18M	4.61M	10.1M	9.65M	10.57M	12.18M	42.55M
Total Debt+	0	672.97K	172.97K	172.97K	172.97K	1.35M	855.47K	678.23K	481.25K	262.87K
Net Debt	-676.14K	378.62K	-3.03M	-9.01M	-7.72M	-12.51M	-69.22M	-41.03M	-26M	-2.99M
Debt / Equity	-	0.04x	0.01x	0.01x	0.01x	0.04x	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-430.66x	-828.25x	-11.74x	-870.64x	-948.63x	-1130.01x	-2171.04x	-132.52x	-	-
Total Equity+	-635.21K	16.77M	21.95M	27.87M	24.38M	33.67M	132.78M	103.43M	91.43M	74.1M
Equity Growth %	0.14%	27.39%	0.31%	0.27%	-0.13%	0.38%	2.94%	-0.22%	-0.12%	-0.19%
Book Value per Share	-4.49	69.41	60.05	38.95	18.14	12.90	18.34	10.62	9.06	6.39
Total Shareholders' Equity	-635.21K	16.77M	21.95M	27.87M	24.38M	33.67M	132.18M	102.83M	90.83M	70.08M
Common Stock	34.12K	73.14K	8.35K	16.2K	28.93K	55.58K	145.98K	146.21K	158.86K	7.25K
Retained Earnings	-9.04M	-17.34M	-27.72M	-40.26M	-55.82M	-70.59M	-96.05M	-129.69M	-162.23M	-201.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	600.38K	600.38K	600.38K	4.02M

Cash Flow

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	-2.39M	-5.9M	-7.97M	-11.32M	-12.44M	-16.93M	-24.25M	-28.36M	-29.06M	-28.2M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-2.38%	-1.47%	-0.35%	-0.42%	-0.1%	-0.36%	-0.43%	-0.17%	-0.02%	0.03%
Net Income	-2.9M	-8.3M	-10.38M	-12.54M	-15.56M	-17.55M	-23.05M	-33.64M	-32.54M	-39.43M
Depreciation & Amortization	0	1.34K	2.63K	1.75K	893	152.36K	164.87K	179.68K	194.32K	209.61K
Stock-Based Compensation	486.27K	732.15K	986.62K	779.7K	715.98K	803.26K	1.45M	3.91M	6.62M	11.84M
Deferred Taxes	0	843.62K	0	-450K	0	0	-166.56K	576K	576K	576K
Other Non-Cash Items	-332.1K	150K	1.31M	377.2K	211.6K	528.77K	68K	378.2K	102K	284.18K
Working Capital Changes	362.68K	668.16K	115.52K	509.85K	2.2M	-866.97K	-2.72M	239.56K	-4.01M	-1.69M
Change in Receivables	0	0	0	-818.34K	818.34K	0	0	0	0	0
Change in Inventory	0	0	0	0	-818.34K	0	0	0	0	-2.13M
Change in Payables	452.98K	105.23K	-306.73K	971.01K	1.14M	-857.31K	-579.14K	-111.72K	1.76M	2M
Cash from Investing+	0	255.75K	-2.13K	0	0	-1.83K	-40.01M	0	0	-5M
Capital Expenditures	0	0	-2.13K	0	0	-1.83K	-40.01M	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	255.75K	0	0	0	0	0	0	0	-5M
Cash from Financing+	1.51M	5.26M	10.88M	17.3M	11.15M	22.9M	120.47M	0	13.83M	9.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-64.8K	6.67M	1.13M	23.22K	7.16M	31.21M	0	31.27K	-3.83M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.39M	-5.9M	-7.97M	-11.32M	-12.44M	-16.93M	-64.26M	-28.36M	-29.06M	-28.2M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-2.38%	-1.47%	-0.35%	-0.42%	-0.1%	-0.36%	-2.79%	0.56%	-0.02%	0.03%
FCF per Share	-16.86	-24.43	-21.81	-15.82	-9.25	-6.49	-8.88	-2.91	-2.88	-2.43
FCF Conversion (FCF/Net Income)	0.82x	0.71x	0.77x	0.90x	0.80x	0.96x	1.05x	0.84x	0.89x	0.72x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-102.85%	-53.65%	-50.33%	-59.64%	-60.46%	-27.79%	-28.48%	-33.4%	-47.29%
Return on Invested Capital (ROIC)	-	-70.57%	-41.54%	-54.76%	-65.89%	-70.24%	-41.66%	-39.68%	-43.1%	-46.13%
Debt / Equity	-	0.04x	0.01x	0.01x	0.01x	0.04x	0.01x	0.01x	0.01x	0.00x
Interest Coverage	-430.66x	-828.25x	-11.74x	-870.64x	-948.63x	-1130.01x	-2171.04x	-132.52x	-	-
FCF Conversion	0.82x	0.71x	0.77x	0.90x	0.80x	0.96x	1.05x	0.84x	0.89x	0.72x

Frequently Asked Questions

Growth & Financials

Citius Pharmaceuticals, Inc. (CTXR) reported $0.2M in revenue for fiscal year 2024.

Citius Pharmaceuticals, Inc. (CTXR) grew revenue by 0.0% over the past year. Growth has been modest.

Citius Pharmaceuticals, Inc. (CTXR) reported a net loss of $40.3M for fiscal year 2024.

Dividend & Returns

Citius Pharmaceuticals, Inc. (CTXR) has a return on equity (ROE) of -47.3%. Negative ROE indicates the company is unprofitable.

Citius Pharmaceuticals, Inc. (CTXR) had negative free cash flow of $20.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Citius Pharmaceuticals, Inc. (CTXR) 10-Year Financial Performance & Capital Metrics

CTXR • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $0
EBITDA -$42M -14.4%
Net Income -$39M -20.3%
EPS (Diluted) -5.97 -7.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -47.29% -41.6%
ROIC -46.13% -7.0%
Debt/Equity 0.00 -32.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Shares diluted 14.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM-14.64%

ROCE

10Y Avg-50.01%

5Y Avg-38.21%

3Y Avg-36.44%

Latest-47.01%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	1.34K	2.63K	1.75K	893	152.36K	164.87K	179.68K	194.32K	209.61K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-1.34K	-2.63K	-1.75K	-893	-152.36K	-164.87K	-179.68K	-194.32K	-209.61K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-0.96%	0.33%	0.49%	-169.62%	-0.08%	-0.09%	-0.08%	-0.08%
Operating Expenses+	3.23M	7.45M	9.99M	13.79M	15.6M	17.71M	23.53M	33.32M	36.73M	42M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.43M	4.52M	7.05M	7.23M	7M	8.9M	11.29M	15.66M	21.91M	18.25M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	1.8M	2.93M	2.94M	6.56M	8.6M	8.81M	12.24M	17.66M	14.82M	11.91M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	11.84M
Operating Income+	-3.23M	-7.45M	-9.99M	-13.79M	-15.6M	-17.71M	-23.53M	-33.32M	-36.73M	-42M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.8%	-1.31%	-0.34%	-0.38%	-0.13%	-0.14%	-0.33%	-0.42%	-0.1%	-0.14%
EBITDA+	-3.23M	-7.45M	-9.98M	-13.79M	-15.6M	-17.56M	-23.37M	-33.14M	-36.54M	-41.79M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.31%	-0.34%	-0.38%	-0.13%	-0.13%	-0.33%	-0.42%	-0.1%	-0.14%
D&A (Non-Cash Add-back)	3.07K	1.34K	2.63K	1.75K	893	152.36K	164.87K	179.68K	194.32K	209.61K
EBIT	-2.89M	-7.45M	-9.99M	-12.52M	-15.55M	-17.53M	-23.04M	-33.06M	-31.97M	-38.85M
Net Interest Income+	-4.43K	-8.19K	-849.98K	0	36.22K	52.39K	250.99K	0	1.18M	758K
Interest Income	3.07K	806	806	0	52.66K	68.07K	261.82K	251.4K	1.18M	758K
Interest Expense	7.5K	8.99K	850.79K	15.84K	16.44K	15.67K	10.84K	251.4K	0	0
Other Income/Expense	327.66K	-846.41K	-398.64K	1.25M	36.22K	162.6K	477.46K	251.4K	4.77M	3.15M
Pretax Income+	-2.9M	-8.3M	-10.38M	-12.54M	-15.56M	-17.55M	-23.05M	-33.06M	-31.97M	-38.85M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	4.43K	8.99K	0	0	16.44K	0	0	576K	576K	576K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.02%	1.02%	1.01%
Net Income+	-2.9M	-8.3M	-10.38M	-12.54M	-15.58M	-17.55M	-23.13M	-33.64M	-32.54M	-39.14M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.28%	-1.86%	-0.25%	-0.21%	-0.24%	-0.13%	-0.32%	-0.45%	0.03%	-0.2%
Net Income (Continuing)	-2.9M	-8.3M	-10.38M	-12.54M	-15.56M	-17.55M	-23.05M	-33.64M	-32.54M	-39.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	600.38K	600.38K	600.38K	4.02M
EPS (Diluted)+	-1.37	-2.29	-1.89	-1.17	-0.77	-0.45	-5.64	-5.76	-5.57	-5.97
EPS Growth %	-0.44%	-0.67%	0.17%	0.38%	0.34%	0.42%	-11.53%	-0.02%	0.03%	-0.07%
EPS (Basic)	-1.37	-2.29	-1.89	-1.17	-0.77	-0.45	-5.64	-5.76	-5.57	-5.97
Diluted Shares Outstanding	141.49K	241.55K	365.5K	715.46K	1.34M	2.61M	7.24M	9.74M	10.09M	11.59M
Basic Shares Outstanding	141.49K	241.55K	365.5K	715.46K	1.34M	2.61M	7.24M	9.74M	9.74M	11.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	736.14K	892.84K	3.42M	10.06M	7.94M	13.98M	72.81M	44.56M	34.37M	14.22M
Cash & Short-Term Investments	676.14K	294.35K	3.2M	9.18M	7.89M	13.86M	70.07M	41.71M	26.48M	3.25M
Cash Only	676.14K	294.35K	3.2M	9.18M	7.89M	13.86M	70.07M	41.71M	26.48M	3.25M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	818.34K	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	8.27M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	14.4K
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	5.4K	21.06M	20.99M	20.99M	21.04M	29.79M	69.61M	69.44M	69.24M	102.43M
Property, Plant & Equipment	0	3.74K	3.24K	1.48K	590	987.78K	829.85K	650.17K	455.86K	246.25K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	1.59M	1.59M	1.59M	1.59M	9.35M	9.35M	9.35M	9.35M	9.35M
Intangible Assets	5.4K	19.4M	19.4M	19.4M	19.4M	19.4M	59.4M	59.4M	59.4M	92.8M
Long-Term Investments	0	0	0	0	0	16.92M	29.18M	0	44.91M	0
Other Non-Current Assets	0	66.97K	2.17K	2.17K	57.09K	57.09K	38.06K	39.97M	-44.88M	38.06K
Total Assets+	741.54K	21.95M	24.42M	31.05M	28.99M	43.77M	142.43M	114M	103.61M	116.65M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.52%	28.6%	0.11%	0.27%	-0.07%	0.51%	2.25%	-0.2%	-0.09%	0.13%
Total Current Liabilities+	1.38M	5.18M	2.47M	3.18M	4.61M	4.1M	3.98M	4.53M	5.78M	35.81M
Accounts Payable	559.15K	909.16K	602.43K	1.57M	2.71M	1.86M	1.28M	1.17M	2.93M	4.93M
Days Payables Outstanding	-	247.09K	83.54K	327.61K	1000K	4.45K	2.83K	2.37K	5.5K	8.58K
Short-Term Debt	0	672.97K	172.97K	172.97K	172.97K	172.97K	177.24K	196.99K	218.38K	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	809.34K	2.67M	0	0	320.52K	1.65M	1.73M	1.57M	-218.38K	0
Current Ratio	0.53x	0.17x	1.39x	3.16x	1.72x	3.41x	18.28x	9.84x	5.95x	0.40x
Quick Ratio	0.53x	0.17x	1.39x	3.16x	1.72x	3.41x	18.28x	9.84x	5.95x	0.17x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	1.75M	4.99M	6.01M	5.66M	6.04M	6.4M	6.74M
Long-Term Debt	0	0	0	0	0	164.58K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	855.47K	678.23K	481.25K	262.87K	21.32K
Deferred Tax Liabilities	0	0	0	0	4.99M	4.99M	4.99M	5.56M	6.14M	6.71M
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	1.38M	5.18M	2.47M	3.18M	4.61M	10.1M	9.65M	10.57M	12.18M	42.55M
Total Debt+	0	672.97K	172.97K	172.97K	172.97K	1.35M	855.47K	678.23K	481.25K	262.87K
Net Debt	-676.14K	378.62K	-3.03M	-9.01M	-7.72M	-12.51M	-69.22M	-41.03M	-26M	-2.99M
Debt / Equity	-	0.04x	0.01x	0.01x	0.01x	0.04x	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-430.66x	-828.25x	-11.74x	-870.64x	-948.63x	-1130.01x	-2171.04x	-132.52x	-	-
Total Equity+	-635.21K	16.77M	21.95M	27.87M	24.38M	33.67M	132.78M	103.43M	91.43M	74.1M
Equity Growth %	0.14%	27.39%	0.31%	0.27%	-0.13%	0.38%	2.94%	-0.22%	-0.12%	-0.19%
Book Value per Share	-4.49	69.41	60.05	38.95	18.14	12.90	18.34	10.62	9.06	6.39
Total Shareholders' Equity	-635.21K	16.77M	21.95M	27.87M	24.38M	33.67M	132.18M	102.83M	90.83M	70.08M
Common Stock	34.12K	73.14K	8.35K	16.2K	28.93K	55.58K	145.98K	146.21K	158.86K	7.25K
Retained Earnings	-9.04M	-17.34M	-27.72M	-40.26M	-55.82M	-70.59M	-96.05M	-129.69M	-162.23M	-201.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	600.38K	600.38K	600.38K	4.02M

Cash Flow

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	-2.39M	-5.9M	-7.97M	-11.32M	-12.44M	-16.93M	-24.25M	-28.36M	-29.06M	-28.2M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-2.38%	-1.47%	-0.35%	-0.42%	-0.1%	-0.36%	-0.43%	-0.17%	-0.02%	0.03%
Net Income	-2.9M	-8.3M	-10.38M	-12.54M	-15.56M	-17.55M	-23.05M	-33.64M	-32.54M	-39.43M
Depreciation & Amortization	0	1.34K	2.63K	1.75K	893	152.36K	164.87K	179.68K	194.32K	209.61K
Stock-Based Compensation	486.27K	732.15K	986.62K	779.7K	715.98K	803.26K	1.45M	3.91M	6.62M	11.84M
Deferred Taxes	0	843.62K	0	-450K	0	0	-166.56K	576K	576K	576K
Other Non-Cash Items	-332.1K	150K	1.31M	377.2K	211.6K	528.77K	68K	378.2K	102K	284.18K
Working Capital Changes	362.68K	668.16K	115.52K	509.85K	2.2M	-866.97K	-2.72M	239.56K	-4.01M	-1.69M
Change in Receivables	0	0	0	-818.34K	818.34K	0	0	0	0	0
Change in Inventory	0	0	0	0	-818.34K	0	0	0	0	-2.13M
Change in Payables	452.98K	105.23K	-306.73K	971.01K	1.14M	-857.31K	-579.14K	-111.72K	1.76M	2M
Cash from Investing+	0	255.75K	-2.13K	0	0	-1.83K	-40.01M	0	0	-5M
Capital Expenditures	0	0	-2.13K	0	0	-1.83K	-40.01M	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	255.75K	0	0	0	0	0	0	0	-5M
Cash from Financing+	1.51M	5.26M	10.88M	17.3M	11.15M	22.9M	120.47M	0	13.83M	9.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-64.8K	6.67M	1.13M	23.22K	7.16M	31.21M	0	31.27K	-3.83M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.39M	-5.9M	-7.97M	-11.32M	-12.44M	-16.93M	-64.26M	-28.36M	-29.06M	-28.2M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-2.38%	-1.47%	-0.35%	-0.42%	-0.1%	-0.36%	-2.79%	0.56%	-0.02%	0.03%
FCF per Share	-16.86	-24.43	-21.81	-15.82	-9.25	-6.49	-8.88	-2.91	-2.88	-2.43
FCF Conversion (FCF/Net Income)	0.82x	0.71x	0.77x	0.90x	0.80x	0.96x	1.05x	0.84x	0.89x	0.72x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-102.85%	-53.65%	-50.33%	-59.64%	-60.46%	-27.79%	-28.48%	-33.4%	-47.29%
Return on Invested Capital (ROIC)	-	-70.57%	-41.54%	-54.76%	-65.89%	-70.24%	-41.66%	-39.68%	-43.1%	-46.13%
Debt / Equity	-	0.04x	0.01x	0.01x	0.01x	0.04x	0.01x	0.01x	0.01x	0.00x
Interest Coverage	-430.66x	-828.25x	-11.74x	-870.64x	-948.63x	-1130.01x	-2171.04x	-132.52x	-	-
FCF Conversion	0.82x	0.71x	0.77x	0.90x	0.80x	0.96x	1.05x	0.84x	0.89x	0.72x

Frequently Asked Questions

Growth & Financials

Citius Pharmaceuticals, Inc. (CTXR) reported $0.2M in revenue for fiscal year 2024.

Citius Pharmaceuticals, Inc. (CTXR) grew revenue by 0.0% over the past year. Growth has been modest.

Citius Pharmaceuticals, Inc. (CTXR) reported a net loss of $40.3M for fiscal year 2024.

Dividend & Returns

Citius Pharmaceuticals, Inc. (CTXR) has a return on equity (ROE) of -47.3%. Negative ROE indicates the company is unprofitable.

Citius Pharmaceuticals, Inc. (CTXR) had negative free cash flow of $20.6M in fiscal year 2024, likely due to heavy capital investments.